Infliximab therapy in two cases of severe neurotuberculosis paradoxical reaction

Medical Journal of Australia

Volumn 202, Issue 3, 2015, Pages 156-158

  Molton, James S ^a   Huggan, Paul J ^a   Archuleta, Sophia ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INFLIXIMAB; ISONIAZID; PREDNISOLONE; RIFAMPICIN; ANTIINFLAMMATORY AGENT; ETHAMBUTOL; MONOCLONAL ANTIBODY; PYRAZINAMIDE; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; BRAIN VENTRICLE PERITONEUM SHUNT; CASE REPORT; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; CEREBROSPINAL FLUID ANALYSIS; COGNITION; FEMALE; HUMAN; NERVE PARALYSIS; NOTE; NUCLEAR MAGNETIC RESONANCE; URINE RETENTION; VISUAL FIELD DEFECT; ANTAGONISTS AND INHIBITORS; MIDDLE AGED; TUBERCULOMA, INTRACRANIAL; TUBERCULOSIS, MENINGEAL;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTITUBERCULAR AGENTS; DEXAMETHASONE; ETHAMBUTOL; FEMALE; HUMANS; ISONIAZID; MIDDLE AGED; PREDNISOLONE; PYRAZINAMIDE; RIFAMPIN; TUBERCULOMA, INTRACRANIAL; TUBERCULOSIS, MENINGEAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928248563     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja14.00716     Document Type: Note

References (12)

1. 1 Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008; 47: e83-e85.
2. 2 Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009; 48: e96-e107.
3. 3 Rivoisy C, Amrouche L, Carcelain G, et al. Paradoxical exacerbation of tuberculosis after TNF antagonist discontinuation: beware of immune reconstitution inflammatory syndrome. Joint Bone Spine 2011; 78: 312-315.
4. 4 Jorge JH, Graciela C, Pablo AP, Luis SH. A life-threatening central nervous system-tuberculosis inflammatory reaction nonresponsive to corticosteroids and successfully controlled by infliximab in a young patient with a variant of juvenile idiopathic arthritis. J Clin Rheumatol 2012; 18: 189-191.
5. 5 Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009; 48: 1429-1432.
6. 6 Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351: 1741-1751.
7. 7 Rock RB, Olin M, Baker CA, et al. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev 2008; 21: 243-261.
8. 8 Roberts MT, Mendelson M, Meyer P, et al. The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports. J Infect 2003; 47: 251-255.
9. 9 Schoeman JF, Springer P, van Rensburg AJ, et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol 2004; 19: 250-257.
10. 10 Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005; 41: 201-208.
11. 11 Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010; 161: 1-9.
12. 12 Vlachaki E, Psathakis K, Tsintiris K, Iliopoulos A. Delayed response to anti-tuberculosis treatment in a patient on infliximab. Respir Med 2005; 99: 648-652.